Patents by Inventor Jason A. Hanko

Jason A. Hanko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9845285
    Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: December 19, 2017
    Assignees: CymaBay Therapeutics, Inc., DiaTex, Inc.
    Inventors: Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
  • Publication number: 20160280636
    Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.
    Type: Application
    Filed: December 3, 2015
    Publication date: September 29, 2016
    Inventors: Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
  • Patent number: 9233914
    Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.
    Type: Grant
    Filed: February 25, 2015
    Date of Patent: January 12, 2016
    Assignees: CYMABAY THERAPEUTICS, INC., DIATEX, INC.
    Inventors: Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
  • Publication number: 20150225333
    Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.
    Type: Application
    Filed: February 25, 2015
    Publication date: August 13, 2015
    Inventors: Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
  • Patent number: 8993797
    Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.
    Type: Grant
    Filed: July 10, 2013
    Date of Patent: March 31, 2015
    Assignee: Cymabay Therapeutics, Inc.
    Inventors: Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
  • Patent number: 8846731
    Abstract: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogs, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.
    Type: Grant
    Filed: October 6, 2011
    Date of Patent: September 30, 2014
    Assignee: FerroKin Biosciences, Inc.
    Inventors: Amy E. Tapper, Hugh Y. Rienhoff, Jr., Stephan D. Parent, Patricia Andres, Jason A. Hanko, Huamin Zhang
  • Patent number: 8829197
    Abstract: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.
    Type: Grant
    Filed: March 7, 2011
    Date of Patent: September 9, 2014
    Assignee: FerroKin Biosciences, Inc.
    Inventors: Amy E. Tapper, Hugh Y. Rienhoff, Jr., Stephan D. Parent, Patricia Andres, Jason A. Hanko, Huamin Zhang
  • Patent number: 8710087
    Abstract: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.
    Type: Grant
    Filed: August 4, 2011
    Date of Patent: April 29, 2014
    Assignee: Ferrokin Biosciences, Inc.
    Inventors: Amy E. Tapper, Hugh Y. Rienhoff, Jr., Stephan D. Parent, Patricia Andres, Jason A. Hanko, Huamin Zhang
  • Publication number: 20140024852
    Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.
    Type: Application
    Filed: July 10, 2013
    Publication date: January 23, 2014
    Applicants: Diatex, Inc., Metabolex, Inc.
    Inventors: Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
  • Patent number: 8507719
    Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: August 13, 2013
    Assignees: Metabolex, Inc.
    Inventors: Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
  • Publication number: 20130158264
    Abstract: Polymorphic forms of the tyrosine kinase inhibitor OSI-906, preparation, pharmaceutical compositions, and uses thereof. The invention includes methods of treating diseases such as cancer, including cancer mediated at least in part by IGF-1 R and/or IR, with the polymorphs and compositions. This Abstract is not limiting of the invention.
    Type: Application
    Filed: June 23, 2011
    Publication date: June 20, 2013
    Inventors: Arlindo L. Castelhano, David A. Enger, Jason A. Hanko, Josef A. Rechka, Jing Teng, Yonglai Yang
  • Publication number: 20120270911
    Abstract: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.
    Type: Application
    Filed: October 6, 2011
    Publication date: October 25, 2012
    Applicant: FERROKIN BIOSCIENCES, INC.
    Inventors: Amy E. Tapper, Hugh Y. Rienhoff, Jr., Stephan D. Parent, Patricia Andres, Jason A. Hanko, Huamin Zhang
  • Publication number: 20120232303
    Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.
    Type: Application
    Filed: May 11, 2012
    Publication date: September 13, 2012
    Applicants: Diatex, Inc., Metabolex, Inc.
    Inventors: Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
  • Publication number: 20120202857
    Abstract: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.
    Type: Application
    Filed: August 4, 2011
    Publication date: August 9, 2012
    Applicant: FERROKIN BIOSCIENCES, INC.
    Inventors: Amy E. Tapper, Hugh Y. Rienhoff, JR., Stephan D. Parent, Patricia Andres, Jason A. Hanko, Huamin Zhang
  • Publication number: 20120196895
    Abstract: The invention relates to novel crystalline forms of (2RS)-1-(4-ethylphenyl)-2-methyl-3-piperidin-1-yl-propan-1-one. The preparation and characterization of the novel crystalline forms according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel crystalline forms, which are useful to treat and/or prevent various conditions such as pathological muscle contracture, myotonic conditions, and spastic paralysis or spasticity caused by various neurologic conditions, and are also useful for the treatment and/or prevention of various types of pain and pathological muscle tension.
    Type: Application
    Filed: January 11, 2010
    Publication date: August 2, 2012
    Applicant: Bionevia Pharmaceuticals, Inc.
    Inventors: Isabel Kalofonos, G. Patrick Stahly, William Martin-Doyle, Dimitris Kalofonos, Jeffrey S. Stults, Jason A. Hanko
  • Patent number: 8203019
    Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.
    Type: Grant
    Filed: April 20, 2006
    Date of Patent: June 19, 2012
    Assignees: Metabolex, Inc., DiaTex, Inc.
    Inventors: Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
  • Patent number: 8063227
    Abstract: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.
    Type: Grant
    Filed: July 14, 2009
    Date of Patent: November 22, 2011
    Assignee: Ferrokin Biosciences, Inc.
    Inventors: Amy E. Tapper, Hugh Y. Rienhoff, Jr., Stephan D. Parent, Patricia Andres, Jason A. Hanko, Huamin Zhang
  • Publication number: 20110281911
    Abstract: The invention relates to substantially enantiopure crystalline salt forms of (2RS)-I-(4-Ethylphenyl)-2-methyl-3-piperidin-1-ylpropan-1-one. The preparation and characterization of the substantially enantiopure crystalline salt forms according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the substantially enantiopure crystalline salt forms, which are useful to treat and/or prevent various conditions such as pathological muscle contracture, myotome conditions, and spastic paralysis or spasticity caused by various neurologic conditions, and are also useful for the treatment and/or prevention of various types of pain and pathological muscle tension.
    Type: Application
    Filed: August 3, 2009
    Publication date: November 17, 2011
    Applicant: Bionevia Pharmaceuticals, Inc.
    Inventors: Isabel Kalofonos, G. Patrick Stahly, William Martin-Doyle, Dimitris Kalofonos, Jeffrey S. Stults, Jason A. Hanko, Jeffrey P. Kiplinger
  • Publication number: 20110275679
    Abstract: The invention relates to crystalline forms of flupirtine, particularly to 1:1 flupirtine hydrochloride maleic acid cocrystal. The preparation and characterization of 1:1 flupirtine hydrochloride maleic acid cocrystal is described. The invention also relates to the therapeutic use of the flupirtine hydrochloride maleic acid cocrystal to treat nervous system disorders, pain disorders, and musculoskeletal disorders and to pharmaceutical compositions containing the cocrystal.
    Type: Application
    Filed: August 6, 2009
    Publication date: November 10, 2011
    Applicant: Bionevia Pharmaceuticals, Inc.
    Inventors: Isabel Kalofonos, Dimitris Kalofonos, Patrick G. Stahly, Jeffrey S. Stults, Jason A. Hanko, Rex A. Shipplett, William Martin-Doyle
  • Patent number: 8003684
    Abstract: Crystalline forms of (+)-R-zileuton, which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of (+)-R-zileuton are characterized by a variety of properties and physical measurements. As well, methods of producing crystalline (+)-R-zileuton, and using it to inhibit 5-lipoxygenase activity in subjects to treat a number of diseases, are also discussed.
    Type: Grant
    Filed: February 21, 2007
    Date of Patent: August 23, 2011
    Assignee: Cornerstone Therapeutics, Inc.
    Inventor: Jason A. Hanko